On Nov 09, major Wall Street analysts update their ratings for $Insulet (PODD.US)$, with price targets ranging from $245 to $300.
J.P. Morgan analyst Robbie Marcus maintains with a buy rating, and adjusts the target price from $250 to $280.
BofA Securities analyst Travis Steed maintains with a buy rating.
Citi analyst Joanne Wuensch maintains with a buy rating, and adjusts the target price from $275 to $283.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and adjusts the target price from $245 to $290.
Jefferies analyst Matthew Taylor maintains with a buy rating, and adjusts the target price from $260 to $300.
Furthermore, according to the comprehensive report, the opinions of $Insulet (PODD.US)$'s main analysts recently are as follows:
After the company's third-quarter earnings surpassed expectations, there is a positive outlook on its performance. The expansion of the Type 2 label in the U.S. at the end of August significantly contributed to the surge in new customer initiations in September, with over a quarter of new U.S. initiations in the third quarter coming from Type 2 diabetes patients.
Here are the latest investment ratings and price targets for $Insulet (PODD.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
